Brief: Tandem Diabetes Care Announces FDA Clearance Of Control-IQ+ Automated Insulin Delivery Tech
Feb 25 (Reuters) - Tandem Diabetes Care Inc TNDM.O: TANDEM DIABETES CARE ANNOUNCES FDA CLEARANCE OF CONTROL-IQ+ AUTOMATED INSULIN DELIVERY TECHNOLOGY FOR PEOPLE WITH TYPE 2 DIABETES TANDEM DIABETES CARE INC: CONTROL-IQ+ IS EXPECTED TO BE AVAILABLE FOR NEW AND EXISTING CUSTOMERS IN UNITED STATES IN MARCH 2025 Source text: ID:nBw934rdga Further company coverage: TNDM.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Tandem Diabetes Care
See all newsU.S. STOCKS ON THE MOVE -VF Corp, Biogen, AbbVie
US STOCKS ON THE MOVE-SpaceX, Humana, AbbVie
U.S. STOCKS ON THE MOVE-SpaceX, Humana, Crescent Energy
MedTech growth concerns likely to overshadow Q3 results, Leerink says
Tandem Diabetes Care, Inc. reports results for the quarter ended June 30 - Earnings Summary